Epiberberine

Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC50s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO- scavenging effect (IC50, 16.83 μM), and can be used for the research of Alzheimer disease[1]. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways[2]. Epiberberinecan be used for the research of diabetic disease[3].

Product Specifications

CAS Number

[6873-09-2]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Beta-secretase; Cholinesterase (ChE)

Type

Natural Products

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Epiberberine.html

Purity

98.46

Solubility

DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COC1=C(OC)C=C2C(CC[N+]3=C2C=C(C=C4)C(C5=C4OCO5)=C3)=C1

Molecular Formula

C20H18NO4+

Molecular Weight

336.36

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Jung HA, et al. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol Pharm Bull. 2009 Aug;32 (8) :1433-8.|[2]Choi JS, et al. Anti-adipogenic effect of epiberberine is mediated by regulation of the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways. Arch Pharm Res. 2015 Dec;38 (12) :2153-62.|[3]Ma H, et al. Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice. Drug Dev Res. 2016 Jun;77 (4) :163-70.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Natural Products

Clinical Information

No Development Reported

Isoform

AChE; BACE1; BChE

Citation 01

Aging (Albany NY) . 2021 Oct 9;13 (19) :23193-23209.|J Biomol Struct Dyn. 2023 Dec;41 (20) :11286-11323.|J Ethnopharmacol. 2024 Jun 12:327:117931.|Molecules. 2024 May 14.